Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 19,068 sh2 trades | $34.71avg. | $661,850.28 | −9.4% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 3,141 sh | $34.71 | $109,024.11 | −5.4% | |
Gheuens SarahChief Medical Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 2,940 sh | $34.71 | $102,047.4 | −3.5% |
Burns James WilliamChief Legal Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 3,280 sh | $34.71 | $113,848.8 | −6.2% |
Milanova TsvetaChief Commercial Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 3,262 sh | $34.71 | $113,224.02 | −6.5% |
Krishnan ViswanadhanChief Corp Dev & Strategy | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 04/02 | 04/06 | 2,959 sh | $34.71 | $102,706.89 | −22.3% |
Krishnan ViswanadhanChief Corp Dev & Strategy | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/05 | 03/09 | 2,959 sh | $27.80 | $82,260.2 | −36.5% |
Theodore James Washburn Jr.Principal Accounting Officer | Agios PharmaceuticalsAGIO | Open-market sale | 03/03 | 03/05 | 5,272 sh | $28.88 | $152,255.36 | −85.9% |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 18,055 sh3 trades | $28.96avg. | $522,872.8 | −9.9% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 5,035 sh4 trades | $28.96avg. | $145,813.6 | −9.3% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 2,223 sh3 trades | $28.96avg. | $64,378.08 | −26.6% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 4,055 sh3 trades | $28.96avg. | $117,432.8 | −5.2% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 5,218 sh4 trades | $28.96avg. | $151,113.28 | −10.6% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 03/02 | 03/03 | 2,868 sh2 trades | $28.96avg. | $83,057.28 | −6.5% | |
Milanova TsvetaChief Commercial Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 01/05 | 01/07 | 2,872 sh | $27.02 | $77,601.44 | −7.6% |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 25/12/30 | 01/02 | 18,703 sh2 trades | $27.09avg. | $506,664.27 | −11.6% | |
Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 25/12/30 | 01/02 | 2,932 sh | $27.09 | $79,427.88 | −7.3% | |
Gheuens SarahChief Medical Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 25/12/30 | 01/02 | 2,932 sh | $27.09 | $79,427.88 | −4.3% |
Burns James WilliamChief Legal Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 25/12/30 | 01/02 | 2,932 sh | $27.09 | $79,427.88 | −8.5% |
Milanova TsvetaChief Commercial Officer | Agios PharmaceuticalsAGIO | Open-market sale10b5-1 plan | 25/12/30 | 01/02 | 2,932 sh | $27.09 | $79,427.88 | −9.1% |